Who is sponsoring T807ALS?

T807ALS is sponsored by Tammie L. S. Benzinger, MD, PhD.

What condition does T807ALS study?

T807ALS studies Amyotrophic Lateral Sclerosis (ALS).

What drugs are being tested in T807ALS?

Interventions: Drug: F 18 T807.

What is the status of T807ALS?

T807ALS is currently COMPLETED.

Last reviewed 2020-09-17 · How we verify

F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis (IND 123119 Protocol B) (T807ALS)

NCT02414230 COMPLETED

The purpose of this research study is to evaluate tau distribution in the brain of subjects with: ALS caused by different genetic mutations, any mutation carriers (with or without symptoms), any non-mutation carrier, any sporadic FTD, normal controls.

Details

Lead sponsor	Tammie L. S. Benzinger, MD, PhD
Status	COMPLETED
Enrolment	9
Start date	2015-02
Completion	2020-06-10

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

Drug: F 18 T807

Primary outcomes

F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance. — 5 years

Countries

United States